Alan Prem KUMAR

Dr Alan Prem Kumar’s group focuses on the study of metastatic disease, specifically in breast cancer. Over 90 percent of the morbidity and mortality that results from cancer is due to metastasis. Thus, the understanding of this process is crucial to the development of novel therapies for cancer patients.

csiapk@nus.edu.sg

Biosketch

Principal Associate, Cancer Science Institute of Singapore, National University of Singapore
Assistant Professor, Medical Science Cluster and Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore
Adjunct Professor, Curtin Medical School, Faculty of Health Sciences, Curtin University, WA, Australia

Year(s) Degree (if applicable) Institute
2000 Ph.D University of North Texas, USA
1995 MSc University of North Texas, USA
1992 BSc University of North Texas, USA
2017 – present Adjunct Professor, Curtin Medical School, Curtin University, Australia
2013 – present Principle Associate, Cancer Science Institute of Singapore, NUS
2013 – present Scientific Advisory Board, Pascual Pharma Inc, Philippines
2012 – present Assistant Professor, Cancer Science Institute of Singapore
2012 – present Assistant Professor, Department of Pharmacology, YLL School of Medicine, NUS
2011 – Present Chairman, Pre-Graduate Students Academic Committee, CSI Singapore
2009 – Present Executive Committee (Education Sub-Committee), SINDA, Singapore
2009 – Present Scientific Advisory Board, GenoMed, Inc., Aventura, FL, USA
2014 – 2017 Adjunct Associate Professor, Department of Biological Sciences, University of North Texas, Denton, Texas, USA
2014 – 2017 Adjunct Principal Research Fellow (Associate Professor), School of Biomedical Sciences, Faculty of Health Sciences, Curtin University, WA, Australia
2012 – 2014 Adjunct Assistant Professor, University of North Texas, USA
2012 – 2014 Visiting Scientist, Curtin University, Western Australia
2012 – 2013 John Nott Cancer Fellow, Cancer Council Western Australia
2011 – 2013 Scientific Advisory Board, Bioexplore, India
2009 – 2013 Scientific Advisory Board, BioSciences Research Institute, Chennai, India
2011 – 2012 Visiting Scientist, University of Western Australia, Western Australia
2010 – 2012 School Advisory Committee, Gan Eng Seng School, Singapore
2010 – 2012 Senior Research Scientist, Department of Pharmacology, YLL School of Medicine, NUS
2010 – 2012 Senior Research Scientist, Cancer Science Institute of Singapore, NUS
2009 – 2010 Senior Research Scientist, National University Medical Institutes, NUS
2004 – 2009 Research Scientist, National University Medical Institutes, NUS
2001 – 2004 Post-Doctoral Fellow, Sidney Kimmel Cancer Center, San Diego, California, USA
1993 – 2000 Teaching Coordinator, University of North Texas, USA
2017 Graduate Mentor of the Year 2017, Yong Loo Lin School of Medicine, NUS
2016 Winner of Publication Impact Factor Award for Adjunct Publishing at Curtin University, Perth, Western Australia
2014 Winner of Publication Impact Factor Award for Adjunct Publishing at Curtin University, Perth, Western Australia
2012 Winner of Publication Impact Factor Award for Adjunct Publishing at Curtin University, Perth, Western Australia
2012 – 2013 Recipient of the John Nott Cancer Fellowship from Cancer Council Western Australia
2008 Recipient of AACR-ITO EN, Ltd. Award in the amount of USD$2,000 at American Association for Cancer Research Annual Meeting in San Diego, CA, USA
2007 Received Award in the amount of USD$1,000 at the Society of Free Radical Biology and Medicine, Washington DC, USA
2001 – 2004 Awarded a Postdoctoral Fellowship at Sidney Kimmel Cancer Center, San Diego, CA, USA for postdoctoral research on the role of nuclear receptors in the transcriptional regulation of human myeloperoxidase in atherosclerosis and Alzheimer’s disease
1995 Recipient of Texas Public Education Grant from University of North Texas, USA
1999 Recipient of Outstanding Teaching Award from Department of Biological Sciences, University of North Texas, USA

Research

Metastatic cancers are generally considered to be incurable; therefore, new prognostic markers are urgently needed to identify patients at the highest risk for developing metastases and to enable oncologists to begin tailoring targeted treatments. We recently identified a novel oncogene, DEAD-box protein DP103 (DDX20; Gemin-3) whose function in various cancers is attributable to its ability to activate oncogenic pathways and long non-coding RNAs whose hyperactivity is functionally linked to cancer progression and to acquisition of resistance to chemotherapy. Current research focuses on better understanding the role of DP103 that offers great potential for the development of more specifically targeted treatment in the battle against cancer and metastatic disease.

Dr Kumar’s second research interest is to understand how nuclear receptors regulate gene expression to affect alterations in phenotype and physiology in response to hormones. Nuclear receptors constitute a discrete gene family encoding ligand-activated transcription factors, which includes orphan receptors whose ligands and functions are unknown. Understanding the novel physiological roles and mechanisms of action of these receptors with special interest in post-translational modification including phosphorylation, acetylation, and SUMOylation will ultimately translate into understanding human disease and ultimately developing novel treatments and therapies.

Over the years, Dr Kumar has forged relationships with scientists and oncologists in cancer research and established industry alignment projects with Davos Life Science, Singapore; GenoMed Inc, USA; Daiichi Sankyo Inc, USA, Pascual Pharma Inc, Philippines and Rexahn Pharmaceuticals, USA.

Lab Members

Selected Publications

1. Chen L, Yuan Y, Kar S, Kanchi MM, Arora S, Kim JE, Koh PF, Yousef E, Samy RP, Shanmugam MK, Tan TZ, Shin SW, Arfuso F, Shen HM, Yang H, Goh BC, Park JI, Gaboury L, Lobie PE, Sethi G, Lim LH*, Kumar AP*. PPARy Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple Negative Breast Cancers. Mol Cancer Ther. 2017 Aug 15. pii: molcanther.0739.2016. doi: 10.1158/1535-7163.MCT-16-0739. [Epub ahead of print]. *co-senior authors (IF= 6.163)

2. Cai W, Chen ZX, Rane G, Singh SS, Choo Z, Tan TZ, Wang C, Yuan Y, Arfuso F, Yap CT, Pongor L, Yang H, Sethi G, Benoukraf T, Tergaonkar V, Kumar AP. Wanted DEAD/H or Alive: Helicases winding up in cancers. JNCI J Natl Cancer Inst. 2017 Jan 25;109(6). pii: djw278. (IF=12.6)

3. Loo SY, Hirpara J, Pandey V, Tuan ZT, Yap CT, Lobie PE, Thiery JP, Goh BC, Pervaiz S, Clement MV, Kumar AP. MnSOD Expression Regulates the Switch between an Epithelial to a Mesenchymal-like Phenotype in Mammary Carcinoma. Antioxid Redox Signal. 2016 Aug 20;25(6):283-99 (IF=7.1)

4. Goh JN, Loo SY, Datta A, Siveen KS, Yap WN, Cai W, Shin EM, Wang C, Kim JE, Chan M, Dharmarajan AM, Lee AS, Lobie PE, Yap CT*, Kumar AP*. microRNAs in breast cancer: regulatory roles governing the hallmarks of cancer. Biol Rev Camb Philos Soc. 2016 May;91(2):409-28. *co-senior authors (IF=10.7)

5. Shin EM, Hay HS, Lee MH, Goh JN, Tan TZ, Sen YP, Lim SW, Yousef EM, Ong HT, Thike AA, Kong X, Wu Z, Mendoz E, Sun W, Salto-Tellez M, Lim CT, Lobie PE, Lim YP, Yap CT, Zeng Q, Sethi G, Lee MB, Tan P, Goh BC, Miller LD, Thiery JP, Zhu T, Gaboury L, Tan PH, Hui KM, Yip GW, Miyamoto S, Kumar AP*, Tergaonkar V*. DEAD-box Helicase DP103 Defines the Metastatic Potential of Human Breast Cancers. J Clin Invest. 2014 Sep 2;124(9):3807-24. *co-senior authors (IF= 13.765)

6. Surana R, Sikka S, Cai W, Shin EM, Warrier SR, Tan HJG, Arfuso F, Fox SA, Dharmarajan AM*, Kumar AP*. Secreted Frizzled Related Proteins: Implications in Cancers. BBA Reviews on Cancer 2014 Jan;1845(1):53-65.*co-senior authors. (IF=9.452)

7. Kanjoormana M, Shanmugam MK, Ramachandran L, Li F, Fong CW, Kumar AP, Tan P, Sethi G. First evidence that g-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-kB pathway. Clin Cancer Res. 2012 Apr 15;18(8):2220-9. (IF=9.619)

8. Rajendran P, Ong TH, Chen L, Li F, Shanmugam MK, Valli S, Abbasi T, Kapoor S, Sharma A, Kumar AP, Hui KM, Sethi G. Suppression of Signal Transducer and Activator of Transcription 3 Activation by Butein Inhibits Growth of Human Hepatocellular Carcinoma in vivo. Clin Cancer Res. 2011 Mar 15;17(6):1425-39. (IF=9.619)

9. Kumar AP, Quake AL, Chang MK, Zhou T, Lim KS, Singh R, Hewitt RE, Salto-Tellez M, Pervaiz S, Clément MV. Repression of NHE1 Expression by PPAR{gamma} Activation Is a Potential New Approach for Specific Inhibition of the Growth of Tumor Cells In vitro and In vivo. Cancer Res. 2009 Nov 15;69(22):8636-44. (IF=9.329)

10. Kumar, AP*; Chang, MKX*; Fliegel, L; Pervaiz, S; Clement, MV. Oxidative repression of NHE1 gene expression involves iron-mediated caspase activity. Cell Death Differ. 2007 Oct;14(10):1733-46.4 *co-lead authors. (IF= 8.184)